* Recursion Pharmaceuticals Inc RXRX.OQ reported a
quarterly
adjusted loss of 39 cents per share for the quarter ended in
January, lower than the same quarter last year, when the company
reported EPS of -34 cents. The mean expectation of six analysts
for the quarter was for a loss of 42 cents per share. Wall
Street expected results to range from -46 cents to -39 cents per
share.
* Revenue rose 13.7% to $13.79 million from a year ago;
analysts
expected $12.65 million.
* Recursion Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 39 cents.
* The company reported a quarterly loss of $91.37 million.
* Recursion Pharmaceuticals Inc shares had fallen by 13.8%
this
quarter and lost 12.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 1.6%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"
Wall Street's median 12-month price target for Recursion
Pharmaceuticals Inc is $12.50
This summary was machine generated from LSEG data May 9 at 10:28
p.m. UTC. All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.42 -0.39 Beat
Dec. 31 2023 -0.45 -0.42 Beat
Sep. 30 2023 -0.38 -0.43 Missed
Jun. 30 2023 -0.37 -0.38 Missed